Last reviewed · How we verify
NCT05699070: DWJ1610
Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects
Phase 1 trial testing DWC202211 100mg in Drug-drug Interaction in 24 participants. Status unknown.
24 April 2023
Quick facts
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 15 February 2023 |
| Primary completion | 24 April 2023 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- DWC202211 100mg — full drug profile →
- DWC202212 5mg — full drug profile →
- DWC202211 100mg + DWC202212 5mg — full drug profile →
Conditions studied
- Drug-drug Interaction — all drugs for Drug-drug Interaction →
Sponsor
Daewoong Pharmaceutical Co. LTD. — full company profile →
Who can join
Adults 19 to 50, any sex, with Drug-drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open-label phase 1 study to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability of DWC202211 and DWC202212 compared to coadministration in healthy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects.
Koh J, Khwarg J, Yu KS, Lee S, et al · · 2025 · PMID 40951691 · DOI 10.2147/dddt.s533428
Verify or expand the search:
- PubMed search for NCT05699070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Drug-drug Interaction
Currently open trials in the same condition.
- NCT06381375 — Drug-drug Interactions With Anti-tuberculous Drugs · recruiting
- NCT06682325 — Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients · recruiting
- NCT05044962 — Kuwa Free! - Live Free! · NA · recruiting
Other Daewoong Pharmaceutical Co. LTD. trials
Trials by the same sponsor.
- NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
- NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
- NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
- NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
- NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05699070 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing